Status:
TERMINATED
Neostigmine For Snoring During DISE
Lead Sponsor:
Emory University
Conditions:
Snoring
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
The study team is seeking a novel treatment for snoring involving local application of a nerve stimulant medication, neostigmine. In this study, neostigmine will be injected into 5 sites of the soft p...
Detailed Description
Snoring is a major problem, affecting 40 million Americans. The disease affects patient and partner sleep quality as well as daytime function. Snoring treatment is limited by device compliance (mouth ...
Eligibility Criteria
Inclusion
- Snoring or mild obstructive sleep apnea
- English-speaking
- Greater than 18 years old
- Able to give informed consent
Exclusion
- On active anti-coagulation medication
- Pregnant women
- Hypersensitivity to neostigmine
- Peritonitis or mechanical obstruction of the intestinal or urinary tract
- Coronary artery disease
- Cardiac arrhythmia
- Recent acute coronary syndrome
- Myasthenia gravis
Key Trial Info
Start Date :
November 14 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 19 2019
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT03316963
Start Date
November 14 2017
End Date
March 19 2019
Last Update
July 2 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Raj C. Dedhia
Atlanta, Georgia, United States, 30308